NASDAQ:ETRA Electra Therapeutics Q3 2026 Earnings Results & Report $9.00 +0.57 (+6.76%) As of 02:27 PM Eastern Electra Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$3.47 versus the -$1.76 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeAfter Market ClosesConference Call4:00 PM ET Electra Therapeutics EPS ResultsActual EPS-$3.47Consensus EPS -$1.76Beat/MissMissed by -$1.71One Year Ago EPSN/AElectra Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Electra Therapeutics Q3 2026 Earnings FAQ Did Electra Therapeutics beat earnings estimates for Q3 2026? Electra Therapeutics (NASDAQ:ETRA) reported earnings of -$3.47 per share for Q3 2026, missing the consensus estimate of -$1.76. The report was announced on Thursday, November 12, 2026. Electra Therapeutics Earnings HeadlinesElectra Therapeutics: A Broken IPO Leaves The SIRP Platform Nearly FreeNovember 17 at 5:00 AM | seekingalpha.comAnalysts Offer Insights on NA Companies: Virgin Galactic Holdings (SPCE) and Electra Therapeutics Inc. (ETRA)November 16 at 1:34 PM | theglobeandmail.comUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.November 19 at 1:00 AM | Profits Run (Ad)Electra Therapeutics (NASDAQ:ETRA) Shares Down 9% After Earnings MissNovember 15, 2026 | americanbankingnews.comElectra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio HighlightsNovember 12, 2026 | finance.yahoo.comElectra Therapeutics Insider Bought Shares Worth $3,605,116, According to a Recent SEC FilingNovember 5, 2026 | marketscreener.comMSee More Electra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Electra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Electra Therapeutics and other key companies, straight to your email. Email Address About Electra TherapeuticsElectra Therapeutics (NASDAQ:ETRA) (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression. The product remains investigational and has not been approved for commercial use. Electra Therapeutics is based in the United States and conducts its development activities through clinical research and collaboration with medical and scientific institutions. The company’s pipeline and geographic operations may evolve as its clinical programs advance.View Electra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.